Details for Patent: 8,603,514
✉ Email this page to a colleague
Which drugs does patent 8,603,514 protect, and when does it expire?
Patent 8,603,514 protects SUBOXONE, EXSERVAN, SYMPAZAN, and KYNMOBI, and is included in four NDAs.
This patent has one hundred and sixty-two patent family members in nineteen countries.
Summary for Patent: 8,603,514
| Title: | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| Abstract: | The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method. |
| Inventor(s): | Yang; Robert K. (Fushing, NY), Fuisz; Richard C. (McLean, VA), Myers; Garry L. (Kingsport, TN), Fuisz; Joseph M. (Washington, DC) |
| Assignee: | MonoSol RX, LLC (Warren, NJ) |
| Application Number: | 11/775,484 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,603,514 |
|
Patent Claim Types: see list of patent claims | Composition; Delivery; Use; |
Drugs Protected by US Patent 8,603,514
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-001 | Aug 30, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION | ⤷ Sign Up | ||
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-003 | Aug 10, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION | ⤷ Sign Up | ||
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-002 | Aug 30, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION | ⤷ Sign Up | ||
| Indivior | SUBOXONE | buprenorphine hydrochloride; naloxone hydrochloride | FILM;BUCCAL, SUBLINGUAL | 022410-004 | Aug 10, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION | ⤷ Sign Up | ||
| Aquestive | EXSERVAN | riluzole | FILM;ORAL | 212640-001 | Nov 22, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-001 | Nov 1, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Otter Pharms | SYMPAZAN | clobazam | FILM;ORAL | 210833-002 | Nov 1, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,603,514
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 077803 | ⤷ Sign Up | |||
| Austria | 536868 | ⤷ Sign Up | |||
| Austria | 536869 | ⤷ Sign Up | |||
| Austria | 553746 | ⤷ Sign Up | |||
| Australia | 2002332118 | ⤷ Sign Up | |||
| Australia | 2002348432 | ⤷ Sign Up | |||
| Australia | 2002362772 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
